2023年4月6日

憐憫BioAnalytics -細胞外的先驅vesicle-based液體活檢對於癌症的早期發現——宣布,已經完成了一係列4100萬美元融資。這種超額認購的融資是由諾瓦利斯LifeSciences Sozo企業的參與,Hatteras Venture Partners, iSelect基金,美國癌症協會的天使和百老彙(一個全風險資本集團)。一輪融資還包括戰略投資從Labcorp和力量,除了強大的現有投資者的參與。憐憫BioAnalytics小說憐憫光環平台解鎖高臨床敏感性和特異性通過同時檢測多種癌症相關的生物標記物表麵硝唑個人tumor-derived細胞外囊泡。和豐富的細胞外囊泡在循環使擺布光環測試運行在一個非常小的體積與一個簡單的pcr讀出血清或血漿。融資所得將用於推進發展和商業化的仁慈光環測試高危肺癌篩查,該公司的主要臨床表現。和肺癌是癌症死亡的主要原因在全球範圍內,有超過350的美國人每天死於肺癌。目前有超過1400萬的美國人推薦年度肺癌篩查,但不到6%的人有資格參與成像篩查項目。這樣一個易於管理的血檢憐憫光環可以幫助解決這一挑戰。這一輪資金還將用於推進臨床項目額外的跡象,包括卵巢癌,80%的病例診斷在三期或四期可憐的長期生存。 And Mercy plans to leverage its Mercy Halo liquid biopsy platform technology to develop a broad portfolio of tests for the early detection of cancer. The data presented last year at the annual meetings of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR), and at the Early Detection of Cancer Conference (EDCC), demonstrated promising preliminary performance for Mercy Halo assays in detecting Stage I and II lung cancer and ovarian cancer. And the company is currently planning and executing studies to validate assay performance in larger independent patient cohorts in these and other indications. Mercy will be presenting additional new data at the upcoming AACR conference in Orlando, Florida this month, and at the upcoming International Society for Extracellular Vesicles (ISEV) annual meeting in Seattle, Washington in May. KEY QUOTES: “Cancer remains a leading cause of death globally, and liquid biopsy-based screening represents a meaningful opportunity to address barriers that contribute to disparities in early cancer detection, including in medically underserved populations. We believe the Mercy Halo testing platform is uniquely capable of delivering high-performing, broadly accessible cancer screening across all communities. A simple, inexpensive blood-based screening test could be a vital new tool to significantly increase patient engagement in lung cancer screening, creating the opportunity to save lives through early detection. We are grateful for the support from Novalis, the American Cancer Society BrightEdge and others, and are humbled by their belief in our mission to relieve suffering and save lives through our unique Mercy Halo technology.” — Mercy BioAnalytics CEO Dawn Mattoon, PhD “Liquid biopsy is an important advance in clinical testing that has not yet been fully realized. Mercy is taking a unique approach designed to address the challenges that have plagued early cancer detection liquid biopsy tests that seek to measure tumor-derived DNA. We have been impressed with Mercy’s early clinical data, their relentless focus on scientific rigor, and thoughtful approach to commercialization. We are excited to partner with the company to further validate their Mercy Halo test portfolio across the most challenging cancers we face.” — Paul Meister, Partner at Novalis LifeSciences, and member of Mercy’s Board of Directors Trending on Pulse 2.0